Increasing Options for the Treatment of Osteoporosis  

Oleh:

Khosla, Sundeep

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 361 no. 08 (Aug. 2009), page 818-820 .
Topik: Osteoporosis

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2009.04 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

More than a decade ago, receptor activator of nuclear factor-{kappa}B ligand (RANKL) was identified as the key molecule mediating osteoclast development, activity, and survival. Since osteoporosis results, in part, from increased osteoclastic bone resorption, the inhibition of RANKL activity has been an obvious therapeutic target. In this issue of the Journal, two articles report pivotal studies that reflect more than 10 years of drug development and that establish the efficacy of a human monoclonal antibody to RANKL, denosumab, in reducing fractures.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali